Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors

Endocrine-Related Cancer

Volumn 14, Issue 2, 2007, Pages 221-232

  Vilar, Eduardo ^a   Salazar, Ramón ^b   Pérez García, Jose ^a   Cortes, Javier ^a   Öberg, Kjell ^c   Tabernero, Josep ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CHLOROZOTOCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTERFERON; KI 67 ANTIGEN; OCTREOTIDE; OXALIPLATIN; PACLITAXEL; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; TEMOZOLOMIDE; THALIDOMIDE;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOID; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG MEGADOSE; HUMAN; MONOTHERAPY; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NEUTROPENIA; PANCREAS ISLET CELL CARCINOMA; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE;

CELL PROLIFERATION; DIGESTIVE SYSTEM NEOPLASMS; HUMANS; KI-67 ANTIGEN; NEUROENDOCRINE TUMORS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34547790801     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-06-0074     Document Type: Review

References (67)

1. Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR & Rubin J 2001 A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 91 1543-1548.
2. Bajetta E, Rimassa L, Carnaghi C, Seregni E, Ferrari L, Di Bartolomeo M, Regalia E, Cassata A, Procopio G & Mariani L 1998 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 83 372-378.
3. Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A, Di Bartolomeo M, Buzzoni R, Celio L, Vitali M et al. 2002 Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Annals of Oncology 13 614-621.
4. Bukowski RM, Johnson KG, Peterson RF, Stephens RL, Rivkin SE, Neilan B & Costanzi JH 1987 A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer 60 2891-2895.
5. Bukowski RM, Tangen C, Lee R, Macdonald JS, Einstein AB Jr, Peterson R & Fleming TR 1992 Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study. Journal of Clinical Oncology 10 1914-1918.
6. Bukowski RM, Tangen CM, Peterson RF, Taylor SA, Rinehart JJ, Eyre HJ, Rivkin SE, Fleming TR & Macdonald JS 1994 Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer 73 1505-1508.
7. Canavese G, Azzoni C, Pizzi S, Corleto VD, Pasquali C, Davoli C, Crafa P, Delle Fave G & Bordi C 2001 p27: a potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior. Human Pathology 32 1094-1101.
8. Chaudhry A, Oberg K & Wilander E 1992 A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. Tumour Biology 13 27-35.
9. Cheng PN & Saltz LB 1999 Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86 944-948.
10. Clarke MR, Baker EE, Weyant RJ, Hill L & Carty SE 1997 Proliferative activity in pancreatic endocrine tumors: association with function, metastases, and survival. Endocrine Pathology 8 181-187.
11. Dodd LG, Kerns BJ, Dodge RK & Layfield LJ 1997 Intratumoral heterogeneity in primary breast carcinoma: Study of Concurrent Parameters. Journal of Surgical Oncology 64 280-288.
12. Engstrom PF, Lavin PT, Moertel CG, Folsch E & Douglass HO Jr 1984 Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. Journal of Clinical Oncology 2 1255-1259.
13. Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET & Eriksson BK 2001 Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92 1101-1107.
14. Gentil Perret A, Mosnier JF, Buono JP, Berthelot P, Chipponi J, Balique JG, Cuilleret J, Dechelotte P & Boucheron S 1998 The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors. American Journal of Clinical Pathology 109 286-293.
15. Hainsworth JD, Spigel DR, Litchy S & Greco FA 2006 Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. Journal of Clinical Oncology 24 3548-3554.
16. Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF & Klimstra DS 2002 Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. Journal of Clinical Oncology 20 2633-2642.
17. Hoege C, Pfander B, Moldovan G-L, Pyrowolakis G & Jentsch S 2002 RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 419 135-141.
18. Isacoff WH, Moss RA, Pecora AL & Fine RL 2006 Temozolomide/ capecitabine therapy for metastatic neuroendocrine tumors of the pancreas. A retrospective review. Journal of Clinical Oncology 24 14023.
19. Jensen RT & Norton JA 1995 Endocrine tumors of the pancreas. In Textbook of Gastroenterology, pp 2131-2166. Eds T Yamada, BH Alpers & C Owyang. Philadelphia: Lippincot.
20. Jorda M, Ghorab Z, Fernandez G, Nassiri M, Hanly A & Nadji M 2003 Low nuclear proliferative activity is associated with nonmetastatic islet cell tumors. Archives of Pathology and Laboratory Medicine 127 196-199.
21. Kaltsas GA, Besser GM & Grossman AB 2004 The diagnosis and medical management of advanced neuroendocrine tumors. Endocrine Reviews 25 458-511.
22. Kawada J, Okita M, Nishida M, Yoshimura Y, Toyooka K & Kubota S 1987 Protective effect of 4,6-O-ethylidene glucose against the cytotoxicity of streptozotocin in pancreatic beta cells in vivo: indirect evidence for the presence of a glucose transporter in beta cells. Journal of Endocrinology 112 375-378.
23. Kawahara M, Kammori M, Kanauchi H, Noguchi C, Kuramoto S, Kaminishi M, Endo H & Takubo K 2002 Immunohistochemical prognostic indicators of gastrointestinal carcinoid tumours. European Journal of Surgical Oncology 28 140-146.
24. Kloppel G, Perren A & Heitz PU 2004 The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Annals of the New York Academy of Sciences 1014 13-27.
25. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R & Yao JC 2004 Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. Journal of Clinical Oncology 22 4762-4771.
26. Kulke MH, Kim H, Stuart K, Clark JW, Ryan DP, Vincitore M, Mayer PJ & Fuchs CS 2004a A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Investigation 22 353-359.
27. Kulke MH, Kim H, Clark JW, Enzinger PC, Lynch TJ, Morgan JA, Vincitore M, Michelini A & Fuchs CS 2004b A phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer 101 934-939.
28. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A & Fuchs CS 2006a Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. Journal of Clinical Oncology 24 401-406.
29. Kulke MH, Wu B, Ryan DP, Enzinger PC, Zhu AX, Clark JW, Earle CC, Michelini A & Fuchs CS 2006b A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Digestive Diseases and Sciences 51 1033-1038.
30. Kulke MH, Stuart K, Earle CC, Bhargava P, Clark JW, Enzinger PC, Meyerhardt J, Attawia M, Lawrence C & Fuchs CS 2006c A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology 24 4044.
31. 177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. Journal of Clinical Oncology 23 2754-2762.
32. Lloyd RV 1998 Utility of Ki-67 as a prognostic marker in pancreatic endocrine neoplasms. American Journal of Clinical Pathology 109 245-247.
33. McCollum AD, Kulke MH, Ryan DP, Clark JW, Shulman LN, Mayer RJ, Battel S & Fuchs CS 2004 Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. American Journal of Clinical Oncology 27 485-488.
34. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M et al. 1999 Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. British Journal of Cancer 81 1351-1355.
35. Modlin IM, Lye KD & Kidd M 2003 A 5-decade analysis of 13 715 carcinoid tumors. Cancer 97 934-959.
36. Moertel CG & Hanley JA 1979 Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clinical Trials 2 327-334.
37. Moertel CG, Hanley JA & Johnson LA 1980 Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. New England Journal of Medicine 303 1189-1194.
38. Moertel CG, Lavin PT & Hahn RG 1982 Phase II trial of doxorubicin therapy for advanced islet cell carcinoma. Cancer Treatment Reports 66 1567-1569.
39. Moertel CG, Rubin J & O'Connell MJ 1986 Phase II study of cisplatin therapy in patients with metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Treatment Reports 70 1459-1460.
40. Moertel CG, Kvols LK, O'Connell MJ & Rubin J 1991 Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68 227-232.
41. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG & Klaassen D 1992 Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. New England Journal of Medicine 326 519-523.
42. Moertel CG, Johnson CM, McKusick MA, Martin JK Jr, Nagorney DM, Kvols LK, Rubin J & Kunselman S 1994 The management of patients with advanced carcinoid tumors and islet cell carcinomas. Annals of Internal Medicine 120 302-309.
43. Murray-Lyon IM, Eddleston AL, Williams R, Brown M, Hogbin BM, Bennett A, Edwards JC & Taylor KW 1968 Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet 2 895-898.
44. O̊berg K 2002 Management of neuroendocrine tumors. In ASCO Educational Book, pp 401-405.
45. Oberg K, Norheim I, Lundqvist G & Wide L 1987 Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin-alone or in combination with 5-FU. Acta Oncologica 26 429-432.
46. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA & Wiedenmann B 2004a Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Annals of Oncology 15 966-973.
47. Oberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, Haglund C, Knigge U, Vatn MH & Valimaki M 2004b Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncologica 43 617-625.
48. Ollivier S, Fonck M, Becouarn Y & Brunet R 1998 Dacarbazine, fluorouracil, and leucovorin in patients with advanced neuroendocrine tumors: a phase II trial. American Journal of Clinical Oncology 21 237-240.
49. Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, Di Fonzo M, Tornatore V, Milione M, Angeletti S, Cattaruzza MS, Ziparo V, Bordi C, Pederzoli P & Delle Fave G 2005 Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocrine-Related Cancer 12 1083-1092.
50. Pape UF, Bohmig M, Berndt U, Tiling N, Wiedenmann B & Plockinger U 2004 Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center. Annals of the New York Academy of Sciences 1014 222-233.
51. Pape U, Tiling N, Bartel C, Plockinger U & Wiedenmann B 2006 Oxaliplatin plus 5-fluorouracil/folinic acid as palliative treatment for progressive malignant gastrointestinal neuroendocrine carcinomas. Journal of Clinical Oncology 24 14074.
52. Pelosi G, Zamboni G, Doglioni C, Rodella S, Bresaola E, Iacono C, Serio G, Iannucci A & Scarpa A 1992 Immunodetection of proliferating cell nuclear antigen assesses the growth fraction and predicts malignancy in endocrine tumors of the pancreas. American Journal of Surgical Pathology 16 1215-1225.
53. Pelosi G, Bresaola E, Bogina G, Pasini F, Rodella S, Castelli P, Iacono C, Serio G & Zamboni G 1996 Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Human Pathology 27 1124-1134.
54. Ramanathan RK, Cnaan A, Hahn RG, Carbone PP & Haller DG 2001 Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Annals of Oncology 12 1139-1143.
55. Rigaud G, Missiaglia E, Moore PS, Zamboni G, Falconi M, Talamini G, Pesci A, Baron A, Lissandrini D, Rindi G et al. 2001 High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Research 61 285-292.
56. Rindi G, Capella C & Solcia E 1998 Cell biology, clinicopathological profile, and classification of gastroenteropancreatic endocrine tumors. Journal of Molecular Medicine 76 413-420.
57. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P et al. 2006 TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv 449 395-401.
58. Roche A, Girish B, Baere T, Baudin E, Boige V, Elias D, Lasser P, Schlumberger M & Ducreux M 2003 Transcatheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. European Radiology V13 136-140.
59. La Rosa S, Sessa F, Capella C, Riva C, Leone BE, Klersy C, Rindi G & Solcia E 1996 Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Archiv 429 323-333.
60. Rougier P & Mitry E 2000 Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 62 73-78.
61. Skinazi F, Zins M, Menu Y, Bernades P & Ruszniewski P 1996 Liver metastases of digestive endocrine tumours: natural history and response to medical treatment. European Journal of Gastroenterology & Hepatology 8 673-678.
62. Sokmensuer C, Gedikoglu G & Uzunalimoglu B 2001 Importance of proliferation markers in gastrointestinal carcinoid tumors: a Clinicopathologic Study. Hepatogastroenterology 48 720-723.
63. Strosberg JR, Choi J, Cantor AB & Kvols LK 2006 Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 13 72-78.
64. Sun W, Lipsitz S, Catalano P, Mailliard JA & Haller DG 2005 Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. Journal of Clinical Oncology 23 4897-4904 (DOI: 10.1200/JCO.2005.03.616).
65. Tomassetti P, Migliori M, Lalli S, Campana D, Tomassetti V & Corinaldesi R 2001 Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours. Annals of Oncology 12 S95-S99.
66. Vilar E, Tabernero J, Casado E, Macarulla T, Ramos FJ, Martinelli E & Saura C 2005 Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. American Journal of Clinical Oncology 28 424.
67. Yasui H, Konishi E, Urasaki K, Yasukawa S & Yanagisawa A 2006 Intratumoral heterogeneity of MIB-1 labelling index in gastric gastrointestinal stromal tumor (GIST). Gastric Cancer V9 223-228.